REGULATORY BODIES IN EUROPE
-
Upload
rahul-khare -
Category
Documents
-
view
230 -
download
0
Transcript of REGULATORY BODIES IN EUROPE
-
8/7/2019 REGULATORY BODIES IN EUROPE
1/17
Regulatory Body in
Europe
Rahul Khare
-
8/7/2019 REGULATORY BODIES IN EUROPE
2/17
Why Regulatory Bodies ???
Regulatory requirements describe what isnecessary for a new drug to be approved formarketing in any particular country.
-
8/7/2019 REGULATORY BODIES IN EUROPE
3/17
EU Clinical Trials Directive
The European Clinical Trials Directive 2001/20/EC (EUCTD)was introduced to establish standardisation of researchactivity in clinical trials throughout the European Community
.
In May 2001, the current EU Directive was published on the conduct of clinical trials in Europe.
The EU Directive (2001/20/EC) relates "to the implementation of good clinical practice (GCP) in the conduct of clinicaltrials on medicinal products for human use'', and is aimed atthe regulation of clinical trials within the European Union
and was transposed by each EU country into its own law
-
8/7/2019 REGULATORY BODIES IN EUROPE
4/17
The EUCTD was transposed into UK law as the Medicines for Human Use (Clinical Trials) Regulations 2004 which cameinto force on 1st May 2004.
The European Union Clinical Trials Directive (2001/20/EC)provides a framework which sets out how clinical trials
investigating the safety or efficacy of a medicinal product inhumans .
-
8/7/2019 REGULATORY BODIES IN EUROPE
5/17
The Clinical Trials Regulations 2004include additional controls.
Establishment of ethics committees on a legal basis.
Each Clinical Trial must have an identified Sponsor whotakes responsibility for its initiation, conduct andmanagement.
Phase 1 pharmacology studies in healthy volunteers require authorisation by the Medicines and Healthcare productsRegulatory Agency (MHRA).
-
8/7/2019 REGULATORY BODIES IN EUROPE
6/17
Cont...
Investigational medicinal products (IMPs) must be manufactured to Good Manufacturing Practice (GMP) standards and the manufacturer must have a manufacturing licence.
The MHRA is empowered to carry out statutory inspectionsof the sponsor, researchers, facilities and manufacturing
organisations for GCP, GMP and pharmacovigilance to helpensure required standards are maintained.
-
8/7/2019 REGULATORY BODIES IN EUROPE
7/17
Aims of CT Directives
Protection of clinical trial subjects.
Procedures for Ethics Committees.
Exchange of information between the regulatory bodies and
the European Medicines Agency (EMA).
Standards for Good Clinical Practice (GCP) & Good Manufa
cturing Practice (GMP).
Reporting of Serious Adverse Events (SAE's).
-
8/7/2019 REGULATORY BODIES IN EUROPE
8/17
Protection of clinical trial subjects
Articles 3, 4 and 5 of the directive pay special attention tothe protection of clinical trial subjects and informed consent.
The Directive requires all trial subjects, or the personse legal representativef if the subject is not able, to giveinformed consent.
Also, there is a requirement to ensure that the minor hasreceived adequate information according to his/her capabilityand understanding.
-
8/7/2019 REGULATORY BODIES IN EUROPE
9/17
Ethic Committees
Articles 6 and 7 of the CT Directive define the proceduresfor Ethics Committees, including a time limit for decisions.
The Ethics Committee will play a key role at the very earlystages of the trial in the document evaluation process.
The Directive states the responsibilities of the Ethics
Committees that involves the opinion on the relevance of theclinical trial and the clinical trial design; the protocol; thesuitability of the investigator and supporting staff; theinvestigators brochure and the quality of facilities.
-
8/7/2019 REGULATORY BODIES IN EUROPE
10/17
Ethics Committee Cont...
There is a provision in the Directive that allows a MemberState to refer questions directly to the regulatory authorityresponsible for regulating clinical trials in each Member State
-
8/7/2019 REGULATORY BODIES IN EUROPE
11/17
Timelines
CT Directive timelines for the assessment of Clinical Trialapplications .
60 days for Medicine Control Agency (MCA) and the Ethics
Committee.
The 60 day time period can be extended in following :
Gene therapy or somatic cell therapy or medicinal products
containing genetically modified organisms - additional 30days.
Products that require external consultation - additional 90days.
Xenogenic cell therapy - no time limit.
-
8/7/2019 REGULATORY BODIES IN EUROPE
12/17
Ethics Committee Cont...
Following commencement of the clinical trial the sponsor isable to make amendments to the protocol but the sponsormust notify the MCA of the reasons for, and the content of
, these amendments. The sponsor must also inform the Ethics Committees concerned. The Ethics Committee and theregulatory body must form an opinion on the proposedamendments within a maximum of 35 days.
-
8/7/2019 REGULATORY BODIES IN EUROPE
13/17
Ethics Committee Cont...
It also requires the sponsor to provide a report to the MCAand Ethics Committee at the end of the trial within 90 daysof completion.
If the trial has to be terminated early this notification periodis reduced to 15 days and a reason for termination must be
provided.
-
8/7/2019 REGULATORY BODIES IN EUROPE
14/17
Exchange of Information
Article 11 of the Directive allows the exchange of clinical trial information across Europe.
A European safety database will be set up for all adverseevents reported to the MCA.
These details will go into a European database, which is
supported by the European Agency for the Evaluation ofMedicinal Products (EMEA).All CT information will be recorded to this database, allowing exchange of information between all Member in particular safety alerts and refusal ofauthorisation. This database will only be accessible to the
regulatory authorities of the States of the EU.
-
8/7/2019 REGULATORY BODIES IN EUROPE
15/17
GCP & GMP
Article 13 of the CT Directive states all manufacturers ofinvestigational medicinal products (IMPs), including placebosand active comparator products, require a manufacturers
license.
That is all IMPs must be manufactured to Good Manufacturi
ng Practice (GMP) . If the IMP is manufactured outside theEU it is the responsibility of the ''Qualified Person'' QP toensure the product has been manufactured according to GMP.
-
8/7/2019 REGULATORY BODIES IN EUROPE
16/17
Adverse Events
Article 17 of the Directive requires notification for all serious adverse events.
As per ICH guidelines, Directive requires all unexpected serious adverse events (SAEs) that are fatal or life threateningto be reported to the regulatory authority and to the EthicsCommittee within 7 days of the sponsors'' knowledge, additi
oninformation should be provided within a further 8 days.
Other SAEs must be reported within 15 days of the sponsors'' knowledge.
-
8/7/2019 REGULATORY BODIES IN EUROPE
17/17
THANK YOU